Site Management/Investigator Payments Featured Articles

1. How To Determine Country Feasibility For Cell And Gene Therapy Clinical Trials 4/17/2024

   Learn how to choose the right location — globally — for your next cell and gene therapy clinical trial.

2. The Results Are In — Survey Reveals Barriers & Opportunities In Site Sustainability 3/27/2024

   Get a better understanding of site-level dynamics with 2024 release of the Society for Clinical Research Sites' (SCRS) Site Landscape Survey.

3. No CRO? No Problem As Curadev Tackles Site Selection For Its First Clinical Trial 3/21/2024

   Curadev COO and CFO Manish Tandon discusses the company's first foray into site selection (all without a CRO), covering a site’s influence on patient recruitment and centricity.

4. Could Consolidating Independent Sites Into Site Networks Be The Research Revolution We Need? 3/15/2024

   The formation of clinical trial site networks appears to be rising in popularity. Understand how these integrated networks can contribute to more effective, patient-centric trials — if done correctly.

5. A Site Perspective On Patient Engagement 3/7/2024

   To gain insight from the perspective of clinical sites, see what this clinician had to say regarding their experience with Greenphire.

6. Channel Your Inner Child To Become A Better Clinical Research Professional 2/28/2024

   Sites, CROs, and sponsors sometimes have contentious relationships. It doesn't have to be that way. Discover how to leverage The Zones of Regulation to better manage emotions and become a better partner and CRP.

7. Site Feasibility Tips For Cell And Gene Therapy Clinical Trials 2/22/2024

   Site feasibility assessment can be challenging. Therefore, it’s essential to have a solid understanding of the regulatory obligations for investigators and sites when it comes to choosing each. 

8. Trends In FDA FY2023 Inspection-Based Warning Letters 2/13/2024

   The U.S. FDA issued 180 warning letters to drug and biologics manufacturers in fiscal year 2023 (FY23) and 94 of them were based on an on-site inspection of the company. This article provides an analysis of trends and observations from the inspection-based letters, as well as additional insight on the agency’s approach to enforcement.

9. A Tribe Called SOS 2/5/2024

   A first-hand account of a first-time industry conference. Dan Schell, chief editor of Clinical Leader, talks about his impressions of the Save Our Sites (SOS) conference that happened in Tucson, AZ on Feb. 2, 2024.

10. Why Pharmas/Biotechs Should Champion Non-Pharmaceutical Interventions For MDR Pathogens 2/5/2024

    Multi-drug resistant (MDR) pathogens are an escalating concern. While the primary focus of MDR pathogen treatment strategies has revolved around the creation of innovative therapeutics, diagnostic tools, and antibiotic stewardship, there has been a limited emphasis on implementing non-pharmaceutical interventions (NPIs). Regardless of what indication your drug's clinical trial is investigating, implementing NPIs will actually help your trial be more successful.